Discovery solubility measurement and assessment of small molecules with drug development in mind

Sinha, 2018, Drug discovery and development: an overview, 19 Berdigaliyev, 2020, An overview of drug discovery and development, Future Med Chem., 12, 939, 10.4155/fmc-2019-0307 Sweetana, 1996, Solubility principles and practices for parenteral drug dosage form development, PDA J Pharm Sci Technol., 50, 330 Di, 2012, Bridging solubility between drug discovery and development, Drug Discov Today., 17, 486, 10.1016/j.drudis.2011.11.007 Manssour- Manssour-Triedo, 2016, Molecular and physicochemical factors governing solubility of the HIV gp41 ectodomain, Biophys J., 111, 700, 10.1016/j.bpj.2016.07.022 Bhattachar, 2017, Developability assessment of clinical candidates, 231 Landis, 2018, Commentary: why pharmaceutical scientists in early drug discovery are critical for influencing the design and selection of optimal drug candidates, AAPS PharmSciTech., 19, 1, 10.1208/s12249-017-0849-3 Evers, 2019, Peptide optimization at the drug discovery-development interface: tailoring of physicochemical properties toward specific formulation requirements, J Pharm Sci., 108, 1404, 10.1016/j.xphs.2018.11.043 Yang, 2020, The evolving druggability and developability space: chemically modified new modalities and emerging small molecules, AAPS Journal., 22, 21, 10.1208/s12248-019-0402-2 Gigante, 2021, Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system, ADMET DMPK., 9, 23 Avdeef, 2016, Equilibrium solubility measurement of ionizable drugs - consensus recommendations for improving data quality, ADMET DMPK., 4, 117, 10.5599/admet.4.2.292 Yalkowsky, 1999 Sou, 2018, Automated assays for thermodynamic (equilibrium) solubility determination, Drug Discov Today: Tech., 27, 11, 10.1016/j.ddtec.2018.04.004 Vertzoni, 2022, UNGAP best practice for improving solubility data quality of orally administered drugs, Eur J Pharm Sci., 168, 10.1016/j.ejps.2021.106043 Ono, 2019, Harmonizing solubility measurement to lower inter-laboratory variance - progress of consortium of biopharmaceutical tools (CoBiTo) in Japan, ADMET DMPK., 7, 183, 10.5599/admet.704 Mathias, 2013, Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy, Mol Pharm., 10, 4063, 10.1021/mp400426f Augustijns, 2012, Supersaturating drug delivery systems: fast is not necessarily good enough, J Pharm Sci., 101, 7, 10.1002/jps.22750 Bevernage, 2013, Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues, Int J Pharm., 453, 25, 10.1016/j.ijpharm.2012.11.026 Bergstrom, 2004, Accuracy of calculated pH-dependent aqueous drug solubility, Eur J Pharm Sci., 22, 387, 10.1016/j.ejps.2004.04.006 Serajuddin, 2007, Salt formation to improve drug solubility, Adv Drug Deliv Rev., 59, 603, 10.1016/j.addr.2007.05.010 Dahan, 2012, The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs, AAPS J., 14, 244, 10.1208/s12248-012-9337-6 Narang, 2015, Role of self-association and supersaturation in oral absorption of a poorly soluble weakly basic drug, Pharm Res., 32, 2579 Mantik, 2019, Cyclodextrin reduces intravenous toxicity of a model compound, J Pharm Sci., 108, 1934, 10.1016/j.xphs.2019.01.004 Murdande, 2010, Solubility advantage of amorphous pharmaceuticals: I, A thermodynamic analysis. J Pharm Sci., 99, 1254 Hancock, 2000, What is the true solubility advantage for amorphous pharmaceuticals?, Pharm Res., 17, 397, 10.1023/A:1007516718048 Lindfors, 2006, Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations, Langmuir., 22, 911, 10.1021/la052367t Kuentz, 2013, In silico prediction of the solubility advantage for amorphous drugs - are there property-based rules for drug discovery and early pharmaceutical development?, Eur J Pharm Sci., 48, 554, 10.1016/j.ejps.2012.11.015 Luder, 2009, In silico prediction of drug solubility: 4. Will simple potentials suffice?, J Comput Chem., 30, 1859, 10.1002/jcc.21173 Murdande, 2011, Solubility advantage of amorphous pharmaceuticals: part 3: is maximum solubility advantage experimentally attainable and sustainable?, J Pharm Sci., 100, 4349, 10.1002/jps.22643 Manchanda, 2019, Nuances in the calculation of amorphous solubility enhancement ratio, J Pharm Sci., 108, 3560, 10.1016/j.xphs.2019.06.020 Trasi, 2017, Non-sink dissolution behavior and solubility limit of commercial tacrolimus amorphous formulations, J Pharm Sci., 106, 264, 10.1016/j.xphs.2016.09.016 Štukelj, 2019, Direct measurement of amorphous solubility, Anal Chem., 91, 7411, 10.1021/acs.analchem.9b01378 Almeida e Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS. Assessment of the amorphous ‘solubility’ of a group of diverse drugs using new experimental and theoretical approaches. Mol Pharm. 2015; 12(2): 484–495. Alsenz, 2007, High throughput solubility measurement in drug discovery and development, Adv Drug Deliv Rev., 59, 546, 10.1016/j.addr.2007.05.007 Könczöl, 2018, Brief overview of solubility methods: recent trends in equilibrium solubility measurement and predictive models, Drug Discov Today: Tech., 27, 3, 10.1016/j.ddtec.2018.06.001 Wyttenbach, 2007, Miniaturized assay for solubility and residual solid screening (SORESOS) in early drug development, Pharm Res., 24, 888, 10.1007/s11095-006-9205-0 Sugano, 2006, High throughput solubility measurement with automated polarized light microscopy analysis, J Pharm Sci., 95, 2115, 10.1002/jps.20628 Macfaul, 2016, On the utility of coupling polarised light microscopy to a solubility assay in drug discovery, J Med Chem Comm., 7, 1123, 10.1039/C6MD00138F Pudipeddi, 2005, Trends in solubility of polymorphs, J Pharm Sci., 94, 929, 10.1002/jps.20302 Saal, 2012, Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks, Eur J Pharm Sci., 47, 589, 10.1016/j.ejps.2012.07.019 Pike, 2020, Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective, Drug Discov Today., 25, 1793, 10.1016/j.drudis.2020.07.013 Berghausen, 2016, Simulated rat intestinal fluid improves oral exposure prediction for poorly soluble compounds over a wide dose range, ADMET DMPK., 4, 35, 10.5599/admet.4.1.258 Hoelke, 2009, Comparison of nephelometric, UV-spectroscopic, and HPLC methods for high-throughput determination of aqueous drug solubility in microtiter plates, Anal Chem., 81, 3165, 10.1021/ac9000089 Skolnik, 2018, Automated supersaturation stability assay to differentiate poorly soluble compounds in drug discovery, J Pharm Sci., 107, 84, 10.1016/j.xphs.2017.05.025 Zhang, 2020, Preformulation studies and enabling formulation selection for an insoluble compound at preclinical stage—from in vitro, in silico to in vivo, J Pharm Sci., 109, 950, 10.1016/j.xphs.2019.10.023 Plum, 2020, Comparison of induction methods for supersaturation: pH shift versus solvent shift, Int J Pharm., 573, 10.1016/j.ijpharm.2019.118862 Danielson, 2017, In silico ADME techniques used in early-phase drug Discovery, 81 Göller, 2020, Bayer’s in silico ADMET platform: a journey of machine learning over the past two decades, Drug Discov Today., 25, 1702, 10.1016/j.drudis.2020.07.001 Bunally, 2019, Using physicochemical measurements to influence better compound design, SLAS Discov., 24, 791, 10.1177/2472555219859845 Avdeef, 2020, Prediction of aqueous intrinsic solubility of druglike molecules using Random Forest regression trained with Wiki-pS0 database, ADMET DMPK., 8, 29, 10.5599/admet.766 Berghausen, 2014, Diagnosing solubility limitations - the example of hydrate formation, ADMET DMPK., 2, 115, 10.5599/admet.2.2.36 Pissot Soldermann, 2020, Discovery of potent, highly selective, and in vivo efficacious, allosteric MALT1 inhibitors by iterative scaffold morphing, J Med Chem., 63, 14576, 10.1021/acs.jmedchem.0c01245 Faller, 2007, Computational approaches to determine drug solubility, Adv Drug Deliv Rev., 59, 533, 10.1016/j.addr.2007.05.005 Wuelfing, 2015, Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species, Mol Pharm., 12, 1031, 10.1021/mp500504q Butler, 2010, The developability classification system: application of biopharmaceutics concepts to formulation development, J Pharm Sci., 99, 4940, 10.1002/jps.22217 Bayliss, 2016, Quality guidelines for oral drug candidates: dose, solubility and lipophilicity, Drug Discov Today., 21, 1719, 10.1016/j.drudis.2016.07.007 Ding, 2012, Developability assessment of clinical drug products with maximum absorbable doses, Int J Pharm., 427, 260, 10.1016/j.ijpharm.2012.02.003